DEA Issues First Federal Registrations to More Than 900 Medical-Marijuana Dispensaries

Breaking news · Medical marijuana · DEA · Federal drug policy · Health policy · Small business taxation · Government accountability · DINA analysis

WASHINGTON — October 31, 2026: The Drug Enforcement Administration has issued the first federal registrations to more than 900 state-licensed medical-marijuana dispensaries, beginning a new phase of federal oversight after the Justice Department placed qualifying medical-marijuana activity under Schedule III controls.

Confirmed federal action: The Justice Department said the initial registrations cover dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. Each recipient had to hold a qualifying state license, apply during the initial federal window and complete a DEA pre-registration investigation.

The department did not name the registered businesses in its announcement. State licensure alone does not guarantee federal registration, and registered dispensaries remain subject to federal security, inventory, recordkeeping and controlled-substance requirements.

What changed

The registrations implement part of an April 23 order issued under 21 U.S.C. § 811(d). That order placed FDA-approved marijuana products and marijuana products handled under qualifying state medical licenses in Schedule III while creating an expedited registration process for licensed manufacturers, distributors and dispensaries.

DEA is beginning with more than 900 dispensaries in seven states. The agency is continuing to process dispensary applications and is separately reviewing applications from medical-marijuana manufacturers and distributors. Those supply-side applications require additional review, including facility inspections, production controls and quota determinations.

Qualifying businesses that applied during the initial 60-day period may, while their applications remain pending, transact with other timely applicants and newly registered entities subject to the order's requirements. That temporary status is not the same as receiving a final registration.

Potential tax consequences

The change may carry major federal tax consequences for businesses that now operate within Schedule III rather than Schedule I. Internal Revenue Code Section 280E denies deductions and credits to businesses trafficking in Schedule I or II controlled substances. Treasury and the IRS previously said the April order generally removes Section 280E as a bar for covered medical-marijuana activities and promised transition guidance.

That does not mean every cannabis business may automatically deduct every expense. Businesses that combine medical and recreational operations may have to separate covered Schedule III activity from activity that remains under Schedule I. Tax treatment can also depend on the effective date, the business's taxable year and forthcoming Treasury guidance.

Why it matters

This is the first time DEA has registered state-licensed medical-marijuana dispensaries under the new framework. For patients, the shift could expand access to federally recognized medical distribution while imposing uniform safeguards. For businesses, registration may reduce legal and tax uncertainty but adds federal compliance costs and inspection exposure.

The transition also creates a two-tier market. Registered entities and timely applicants may transact within the protected framework, while businesses that missed the application window, fail federal review or mix covered and non-covered activities may face different enforcement and tax consequences.

DINA analysis: publish the registration ledger

DINA analysis: DOJ's announcement describes the scale of the first approvals but withholds the information needed to evaluate consistency. A transparent rollout should identify each registration, its state, business type, approval date and any material conditions, while protecting legitimate security details.

The strongest accountability test is whether similarly situated applicants receive comparable review and whether DEA clearly explains denials, delays and compliance expectations. Regulators should also disclose how they will handle businesses serving both medical and adult-use markets, applicants with past convictions, interstate supply restrictions and state programs whose rules differ from traditional pharmacy controls.

Tax relief should likewise be measured rather than assumed. Treasury and IRS guidance should explain expense allocation, transition dates, amended-return treatment and the records required from businesses with mixed Schedule I and Schedule III operations.

Urgent follow-up and public-records priorities

• Obtain DEA's complete registration list, including approval dates, states, business categories and material conditions.
• Request application, approval, denial and withdrawal totals by state and applicant type.
• Obtain the pre-registration investigation checklist, inspection standards, average processing times and appeal procedures.
• Track manufacturer and distributor registrations to determine whether the federally compliant supply chain can meet patient demand.
• Obtain Treasury and IRS transition guidance on Section 280E, mixed-use businesses and the effective taxable year.
• Determine how DEA will treat operators serving both medical and recreational markets and whether covered inventory must be physically or financially segregated.
• Monitor enforcement actions against businesses that transact outside the registered or timely-applicant network.

Sources

1. U.S. Department of Justice — first federal registrations for more than 900 medical-marijuana dispensaries, October 30, 2026
2. Drug Enforcement Administration — marijuana rescheduling regulatory actions and registration resources
3. Federal Register — Schedule III final order and expedited registration framework, April 28, 2026
4. U.S. Treasury — planned tax guidance following medical-marijuana rescheduling
5. U.S. House Office of the Law Revision Counsel — 26 U.S.C. § 280E
6. The Associated Press — registrations, pending applications and unresolved implementation questions, October 31, 2026